Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (324)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05235737 | The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab(PIRG) | unknown | Phase 4 | 36 | Medical University of SilesiaOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT03707847 | Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL | unknown | Phase 4 | 20 | Mingzhi ZhangOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT01746992 | CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma | unknown | Phase 4 | 200 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Aug 31, 2023source: clinicaltrials